Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
Rachel S Gross,Tanayott Thaweethai,Erika B Rosenzweig,James Chan,Lori B Chibnik,Mine S Cicek,Amy J Elliott,Valerie J Flaherman,Andrea S Foulkes,Margot Gage Witvliet,Richard Gallagher,Maria Laura Gennaro,Terry L Jernigan,Elizabeth W Karlson,Stuart D Katz,Patricia A Kinser,Lawrence C Kleinman,Michelle F Lamendola-Essel,Joshua D Milner,Sindhu Mohandas,Praveen C Mudumbi,Jane W Newburger,Kyung E Rhee,Amy L Salisbury,Jessica N Snowden,Cheryl R Stein,Melissa S Stockwell,Kelan G Tantisira,Moriah E Thomason,Dongngan T Truong,David Warburton,John C Wood,Shifa Ahmed,Almary Akerlundh,Akram N Alshawabkeh,Brett R Anderson,Judy L Aschner,Andrew M Atz,Robin L Aupperle,Fiona C Baker,Venkataraman Balaraman,Dithi Banerjee,Deanna M Barch,Arielle Baskin-Sommers,Sultana Bhuiyan,Marie-Abele C Bind,Amanda L Bogie,Tamara Bradford,Natalie C Buchbinder,Elliott Bueler,Hülya Bükülmez,B J Casey,Linda Chang,Maryanne Chrisant,Duncan B Clark,Rebecca G Clifton,Katharine N Clouser,Lesley Cottrell,Kelly Cowan,Viren D'Sa,Mirella Dapretto,Soham Dasgupta,Walter Dehority,Audrey Dionne,Kirsten B Dummer,Matthew D Elias,Shari Esquenazi-Karonika,Danielle N Evans,E Vincent S Faustino,Alexander G Fiks,Daniel Forsha,John J Foxe,Naomi P Friedman,Greta Fry,Sunanda Gaur,Dylan G Gee,Kevin M Gray,Stephanie Handler,Ashraf S Harahsheh,Keren Hasbani,Andrew C Heath,Camden Hebson,Mary M Heitzeg,Christina M Hester,Sophia Hill,Laura Hobart-Porter,Travis K F Hong,Carol R Horowitz,Daniel S Hsia,Matthew Huentelman,Kathy D Hummel,Katherine Irby,Joanna Jacobus,Vanessa L Jacoby,Pei-Ni Jone,David C Kaelber,Tyler J Kasmarcak,Matthew J Kluko,Jessica S Kosut,Angela R Laird,Jeremy Landeo-Gutierrez,Sean M Lang,Christine L Larson,Peter Paul C Lim,Krista M Lisdahl,Brian W McCrindle,Russell J McCulloh,Kimberly McHugh,Alan L Mendelsohn,Torri D Metz,Julie Miller,Elizabeth C Mitchell,Lerraughn M Morgan,Eva M Müller-Oehring,Erica R Nahin,Michael C Neale,Manette Ness-Cochinwala,Sheila M Nolan,Carlos R Oliveira,Onyekachukwu Osakwe,Matthew E Oster,R Mark Payne,Michael A Portman,Hengameh Raissy,Isabelle G Randall,Suchitra Rao,Harrison T Reeder,Johana M Rosas,Mark W Russell,Arash A Sabati,Yamuna Sanil,Alice I Sato,Michael S Schechter,Rangaraj Selvarangan,S Kristen Sexson Tejtel,Divya Shakti,Kavita Sharma,Lindsay M Squeglia,Shubika Srivastava,Michelle D Stevenson,Jacqueline Szmuszkovicz,Maria M Talavera-Barber,Ronald J Teufel 2nd,Deepika Thacker,Felicia Trachtenberg,Mmekom M Udosen,Megan R Warner,Sara E Watson,Alan Werzberger,Jordan C Weyer,Marion J Wood,H Shonna Yin,William T Zempsky,Emily Zimmerman,Benard P Dreyer,RECOVER-Pediatric Consortium
DOI: https://doi.org/10.1371/journal.pone.0285635
IF: 3.7
2024-05-07
PLoS ONE
Abstract:Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults. Observations: We describe the protocol for the Pediatric Observational Cohort Study of the NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of four cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n = 10,000). The de novo cohort incorporates three tiers of data collection: 1) remote baseline assessments (Tier 1, n = 6000); 2) longitudinal follow-up for up to 4 years (Tier 2, n = 6000); and 3) a subset of participants, primarily the most severely affected by PASC, who will undergo deep phenotyping to explore PASC pathophysiology (Tier 3, n = 600). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science. Conclusions and relevance: RECOVER-Pediatrics seeks to characterize the clinical course, underlying mechanisms, and long-term effects of PASC from birth through 25 years old. RECOVER-Pediatrics is designed to elucidate the epidemiology, four-year clinical course, and sociodemographic correlates of pediatric PASC. The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions. Clinical trials.gov identifier: Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT05172011.